Argenx (ENXTBR:ARGX) Stock Faces Margin Compression As 32.3% Profitability Tests Bullish NarrativeSimplywall·1 day ago, 04:17 PMARGX-0.69%
ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strongQuartr·2 days ago, 10:04 AMARGX-0.69%
ARGX: Q2 2026 delivered 60% sales growth and expanded VYVGART reach, with strong profit gainsQuartr·Jul 23 at 12:48 AMARGX-0.69%
argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billionPUBT·Jul 23 at 12:12 AMARGX-0.69%
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business UpdateUnusual Whales·Jul 23 at 12:02 AMARGX-0.69%
argenx SE GAAP EPS of $7.32 beats by $1.12, revenue of $1.52B beats by $90Mbusinessinsider·Jul 23 at 12:26 AMARGX-0.69%
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer | MRK Stock NewsStockTitan·Jul 23 at 04:00 AMREGN+0.63%
Amgen submits data to FDA, challenges proposed Tavneos market withdrawalPUBT·2 days ago, 07:24 AMAMGN+1.22%
argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMarket Beat·1 day ago, 11:18 AMARGX-0.69%
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc.Market Beat·1 day ago, 04:04 AMVRTX+0.90%
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSSPR Newswire·Jul 21 at 06:00 PMREGN+0.63%
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA LawMorningStar·Jul 21 at 03:14 PMREGN+0.63%
